Hanne Haahr

Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steady‐state conditions in type 1 diabetes

Tim Heise, Lidia Hermanski, Leszek Nosek et al. · Diabetes Obesity and Metabolism · 2012 · 399 citations

Medicine, Endocrinology, Pharmacology +17

Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes

Tim Heise, Leszek Nosek, Susanne Gammelgaard Bøttcher et al. · Diabetes Obesity and Metabolism · 2012 · 329 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

Insulin Detemir Is Associated With More Predictable Glycemic Control and Reduced Risk of Hypoglycemia Than NPH Insulin in Patients With Type 1 Diabetes on a Basal-Bolus Regimen With Premeal Insulin Aspart

P Vague, Jean-Louis Sélam, Svein Skeie et al. · Diabetes Care · 2003 · 294 citations · Full text

Medicine, Endocrinology, Internal Medicine +17

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

Tim Heise, Thomas R. Pieber, Thomas Danne et al. · Clinical Pharmacokinetics · 2017 · 180 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine

Tim Heise, Ulrike Hövelmann, Leszek Nosek et al. · Expert Opinion on Drug Metabolism & Toxicology · 2015 · 147 citations

Medicine, Pharmacokinetics, Pharmacology +17